Loxiglumide

Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.

Signaling Pathways >> GPCR/G Protein >> Cholecystokinin Receptor

Research Areas >> Metabolic Disease

CCK-1 receptor[1]

The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest)[1].

Rats[1] At 24 h after induction of acute hemorrhagic pancreatitis, rats are divided into four different treatment groups: standard rat chow (AP-C); standard rat chow with pancreatic rest (AP-R); standard rat chow with pancreatic stimulation (AP-S); and standard rat chow with pancreatic rest, followed by pancreatic stimulation (AP-R/S). Rats in the AP-C group receive 2 mL/kg body weight saline orally (po) via an orogastric tube twice daily (09:00 and 21:00 h) for 10 d; the AP-R group receive 50 mg/kg body weight of CCK-1 receptor antagonist Loxiglumide dissolved in 2 mL distilled water po twice daily for 10 d; the AP-S group receive 25 mg/kg body weight protease inhibitor Camostat, which is known to stimulate endogenous CCK release, dissolved in 2 mL distilled water po twice daily for 10 d; and the AP-R/S group receive 50 mg/kg body weight Loxiglumide twice daily for the first 5 d followed by 25 mg/kg body weight camostat twice daily for the next 5 d. Rats are fed ad libitum. On day 12 at 24 h after the last treatment and overnight fasting, pancreatic exocrine function and histological examination of the pancreas are performed.

[1]. Jia D, et al. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats. World J Gastroenterol. 2015 Jul 7;21(25):7742-53.

Caerulein ammonium salt | Gastrin I (human) | Nastorazepide | Proglumide | Sograzepide | Tarazepide | CCK-A receptor inhibitor 1 | CCK-B Receptor Antagonist 1 | 1H-Indole-2-carboxamide, N-[(3R)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | Gastrin/CCK antagonist 1 | GI 181771 | Mini Gastrin I, human | SR 146131

MOLECULAR FORMULA :

C21-H30-Cl2-N2-O5

MOLECULAR WEIGHT :

461.43

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

460 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JSONAU Journal of Surgical Oncology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1969- Volume(issue)/page/year: 53,47,1993

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

450 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JSONAU Journal of Surgical Oncology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1969- Volume(issue)/page/year: 53,47,1993

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Subcutaneous

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

500 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JSONAU Journal of Surgical Oncology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1969- Volume(issue)/page/year: 53,47,1993

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

396 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4769389